Experts and Doctors on influenza b virus in United States


Locale: United States
Topic: influenza b virus

Top Publications

  1. Stray S, Pittman L. Subtype- and antigenic site-specific differences in biophysical influences on evolution of influenza virus hemagglutinin. Virol J. 2012;9:91 pubmed publisher
    ..This suggests that the significance of antibody binding in selecting new variants may also be variable for different antigenic sites and influenza subtypes. ..
  2. Xie D. Fluorescent dye labeled influenza virus mainly infects innate immune cells and activated lymphocytes and can be used in cell-mediated immune response assay. J Immunol Methods. 2009;343:42-8 pubmed publisher
  3. Ilyushina N, Ikizler M, Kawaoka Y, Rudenko L, Treanor J, Subbarao K, et al. Comparative study of influenza virus replication in MDCK cells and in primary cells derived from adenoids and airway epithelium. J Virol. 2012;86:11725-34 pubmed publisher
    ..NHBE cultures could be considered for use as a screening step for evaluating the restricted replication of influenza vaccine candidates. ..
  4. Poland G, Jacobson R, Ovsyannikova I. Influenza virus resistance to antiviral agents: a plea for rational use. Clin Infect Dis. 2009;48:1254-6 pubmed publisher
  5. Zhao C, Collins M, Hsiang T, Krug R. Interferon-induced ISG15 pathway: an ongoing virus-host battle. Trends Microbiol. 2013;21:181-6 pubmed publisher
    ..Only the antiviral activity of human and non-human primate ISG15s can be blocked, providing one possible explanation for the restriction of influenza B virus to humans. ..
  6. Dopp J, Wiegert N, Moran J, Francois M, Radford K, Thomas H, et al. Effect of annual influenza immunization on antibody response in lung transplant patients. Prog Transplant. 2009;19:153-9 pubmed
    ..Annual influenza vaccination in lung transplant subjects produces similar immune responses in 2 consecutive years, indicating that these patients are not at significantly increased risk of vaccine failure. ..
  7. Smith K, Colvin C, Weber P, Spatz S, Coussens P. High titer growth of human and avian influenza viruses in an immortalized chick embryo cell line without the need for exogenous proteases. Vaccine. 2008;26:3778-82 pubmed publisher
    ..In addition to offering a significant improvement in vaccine production, PBS-1 cells should prove valuable in diagnostics and as a cell line of choice for influenza virus research. ..
  8. Mosterín Höpping A, Fonville J, Russell C, James S, Smith D. Influenza B vaccine lineage selection--an optimized trivalent vaccine. Vaccine. 2016;34:1617-1622 pubmed publisher
    ..We describe a lineage selection strategy that optimizes protection against influenza B using the standard trivalent vaccine as a potentially cost effective alternative to quadrivalent vaccines. ..
  9. Hayney M, Moran J, Wiegert N, Burlingham W. Lung transplant patients' T cell responses to influenza vaccine viruses between seasons. Vaccine. 2008;26:2596-600 pubmed publisher
    ..The magnitude of the T cell responses in lung transplant patients is similar to those of healthy control individuals. These responses may be important in T cell memory. ..

More Information


  1. Tasian S, Park J, Martin E, Englund J. Influenza-associated morbidity in children with cancer. Pediatr Blood Cancer. 2008;50:983-7 pubmed publisher
    ..Influenza infection should be considered in febrile children with respiratory symptoms during the respiratory viral season, as well as concurrent bacterial or fungal infections. ..
  2. Chung J, Flannery B, Thompson M, Gaglani M, Jackson M, Monto A, et al. Seasonal Effectiveness of Live Attenuated and Inactivated Influenza Vaccine. Pediatrics. 2016;137:e20153279 pubmed publisher
    ..We observed lower effectiveness of LAIV compared with IIV against influenza A/H1N1pdm09 but not A(H3N2) or B among children and adolescents, suggesting poor performance related to the LAIV A/H1N1pdm09 viral construct. ..
  3. Danziger Isakov L, Cherkassky L, Siegel H, McManamon M, Kramer K, Budev M, et al. Effects of influenza immunization on humoral and cellular alloreactivity in humans. Transplantation. 2010;89:838-44 pubmed publisher
    ..Because the strength of the alloresponse influences long-term graft function, our results suggest that further investigation of alloimmune monitoring after vaccination is needed. ..
  4. Landry M, Cohen S, Ferguson D. Real-time PCR compared to Binax NOW and cytospin-immunofluorescence for detection of influenza in hospitalized patients. J Clin Virol. 2008;43:148-51 pubmed publisher
    ..Further studies are needed to determine the effect of influenza RT-PCR on patient management and costs in hospitalized patients. ..
  5. Englund J, Walter E, Gbadebo A, Monto A, Zhu Y, Neuzil K. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. Pediatrics. 2006;118:e579-85 pubmed
    ..The need for multiple doses of vaccine to produce potentially protective antibody levels in children needs to be considered, even when vaccine is in short supply. ..
  6. Perwitasari O, Torrecilhas A, Yan X, Johnson S, White C, Tompkins S, et al. Targeting cell division cycle 25 homolog B to regulate influenza virus replication. J Virol. 2013;87:13775-84 pubmed publisher
    ..Importantly, NSC95397 treatment protects mice against lethal influenza virus challenge. The findings establish CDC25B as a pro-influenza A virus host factor that may be targeted as a novel influenza A therapeutic strategy. ..
  7. Santos J, Finch C, Sutton T, Obadan A, Aguirre I, Wan Z, et al. Development of an Alternative Modified Live Influenza B Virus Vaccine. J Virol. 2017;91: pubmed publisher
    ..The availability of attenuated IAV and IBV backbones based on contemporary strains offers alternative platforms for the development of LAIVs that may overcome current limitations. ..
  8. Domachowske J, Pankow Culot H, Bautista M, Feng Y, Claeys C, Peeters M, et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis. 2013;207:1878-87 pubmed publisher
    ..QIV may offer improved protection against influenza B in children compared with current trivalent vaccines. ..
  9. Park J, Lee M, Lee E, Song Y, Choi Y, Winthrop K, et al. Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2017;76:1559-1565 pubmed publisher
    ..8% in groups 1, 2, 3 and 4, respectively (p=NS). Temporary MTX discontinuation improves the immunogenicity of seasonal influenza vaccination in patients with RA. Trial registration number is:, NCT02748785. ..
  10. Sridharan H, Zhao C, Krug R. Species specificity of the NS1 protein of influenza B virus: NS1 binds only human and non-human primate ubiquitin-like ISG15 proteins. J Biol Chem. 2010;285:7852-6 pubmed publisher
    ..Consequently, the ISG15 proteins of humans and non-human primates are the only mammalian ISG15 proteins that would bind NS1B. ..
  11. Imai M, Watanabe S, Kawaoka Y. The cytoplasmic tail domain of influenza B virus hemagglutinin is important for its incorporation into virions but is not essential for virus replication in cell culture in the presence of compensatory mutations. J Virol. 2012;86:11633-44 pubmed publisher
    ..They also demonstrate that the domain is not absolutely required for virus viability in cell culture in the presence of compensatory mutations. ..
  12. Kim Y, Narayanan S, Chang K. Inhibition of influenza virus replication by plant-derived isoquercetin. Antiviral Res. 2010;88:227-35 pubmed publisher
    ..Our results suggest that isoquercetin may have the potential to be developed as a therapeutic agent for the treatment of influenza virus infection and for the suppression of resistance in combination therapy with existing drugs...
  13. Yuan W, Krug R. Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein. EMBO J. 2001;20:362-71 pubmed
    ..Influenza A virus employs a different strategy: its NS1 protein does not bind the ISG15 protein, but little or no ISG15 protein is produced during infection. We discuss the likely basis for these different strategies. ..
  14. Block S, Yogev R, Hayden F, Ambrose C, Zeng W, Walker R. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Vaccine. 2008;26:4940-6 pubmed publisher
    ..g., hematopoietic stem cell transplant recipients) for 7 days after vaccination. ..
  15. Zhao C, Denison C, Huibregtse J, Gygi S, Krug R. Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. Proc Natl Acad Sci U S A. 2005;102:10200-5 pubmed
    ..By targeting a wide array of constitutively expressed proteins, ISG15 conjugation greatly extends the repertoire of cellular functions that are affected by IFN-alpha/beta. ..
  16. McNeill K, Vaughn B, Brundage M, Li Y, Poropatich R, Gaydos J. Clinical presentations for influenza and influenza-like illness in young, immunized soldiers. Mil Med. 2005;170:94-7 pubmed
    ..3% of these had an infiltrate. Clinical findings did not differentiate ILI caused by the various agents. Only 29 cases of influenza occurred in approximately 7,200 person-years of observation, supporting the use of influenza vaccine...